Sunitinib
Sunitinib was approved on January 26, 2006 by FDA for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib is a small-molecule which is administered orally and it is multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs and other RTKs including RET, CSF-1R, and flt3.
Primary Characteristics
Sunitinib is also known as Sunitinib malate.
It belongs to Receptor tyrosine kinase (RTK) inhibitor pharmacological group on the basis of mechanism of action.
Non-proprietary name: Sunitinib.
Pharmacokinetics
Absorption: Sunitinib has an pre-systemic (first-pass) metabolism accounts for 90% (±90%).
Distribution: Sunitinib has a plasma protein binding is 95%.
Elimination: plasma half-life is 40 to 60 hours.
Advertisement
Indications
Sunitinib is primarily indicated in conditions like Gastrointestinal stromal tumour, Renal carcinoma.
Contraindications
Sunitinib is contraindicated in conditions like Hypersensitivity to the drug.
Dosage
None recorded.
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Sunitinib is known to cause more or less tolerable side effects which are usually transient. These include Blister or rash on the palms of the hands and soles of the feet, Cracking of skin, Diarrhea, Dyspepsia , GI disorders, Hair discoloration, Mouth irritation, Mouth sores, Nausea, Skin discoloration, Skin dryness, Skin thicking, Stomatitis, Swelling , Taste disturbance, Vomiting .
Warnings / Precautions
Available Brands
Drug Classification
- 1.8.2 — Cytotoxic (anti-neoplastic) drugs
Manufacturers
Manufacturers of Sunitinib in Pakistan: